This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Osiris Therapeutics Takes a Bumpy Ride

"I'm concerned because when you inject MSCs into a patient, the cells go everywhere and we don't know what will happen. Most likely nothing, but we don't know," says Derynk, who serves as co-director of the UCSF Institution for Regeneration Medicine.

"I am comfortable with the use of MSCs to regenerate into new mesenchymal tissue, but when it comes to treating inflammatory diseases, I'm not comfortable because I don't think all the science is there yet," he added.

Last December, results from a phase II study of Prochymal used in combination with steroids in GVHD patients showed that 29 of 31 patients, or 94%, responded to Prochymal treatment, while 23 patients, or 74%, achieved a complete response, meaning they experienced a total clinical resolution of their GVHD. Osiris said the response shown by Prochymal was double what is typically seen when patients are treated with steroids alone.

But a closer look at this study reveals some flaws and suggests that Osiris might be overselling Prochymal's efficacy.

The patients in Osiris' GVHD study appear to be a relatively easy to treat. For instance, 100% of the GVHD patients enrolled received their bone-marrow transplants from matched donors, which makes them more likely to respond to treatment compared to patients who receive bone marrow from unmatched donors, according to published research.
3 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
OSIR $18.73 0.00%
AAPL $113.29 0.00%
FB $91.01 0.00%
GOOG $630.38 0.00%
TSLA $248.48 0.00%

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs